CN105169143A - Traditional Chinese medicinal composition for treating melanin and preparation method of traditional Chinese medicinal composition - Google Patents
Traditional Chinese medicinal composition for treating melanin and preparation method of traditional Chinese medicinal composition Download PDFInfo
- Publication number
- CN105169143A CN105169143A CN201510561135.XA CN201510561135A CN105169143A CN 105169143 A CN105169143 A CN 105169143A CN 201510561135 A CN201510561135 A CN 201510561135A CN 105169143 A CN105169143 A CN 105169143A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicinal composition for treating melanin and a preparation method of the traditional Chinese medicinal composition, and belongs to the field of traditional Chinese medicine. The traditional Chinese medicinal composition capable of treating melanin provided by the invention is mainly prepared from various traditional Chinese medicines including herba cistanche, polygonum cuspidatum, common andrographis herb, fructus corni and the like. The traditional Chinese medicinal composition, when used for treating melanin, can be used for significantly inhibiting melanin cell proliferation and inducing cell apoptosis; and the medicine is low in side effect and is suitable to be developed as a medicine for treating melanin.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to one and be used for the treatment of melanomatous Chinese medicine composition and preparation method thereof.
Background technology
Malignant melanoma is the tumor produced by skin and other organ melanocytes.Cutaneous melanoma shows as pigmentosa skin lesion and occurs obviously to change in several months or several years.Though its sickness rate is low, its grade of malignancy is high, and transfer occurs early, and mortality rate is high, and therefore early diagnosis, early treatment are very important.Malignant melanoma betides adult mostly, and the case of huge property congenital nevus cell nevus secondary canceration is more common in child.Melanoma etiology is illustrated not yet completely.Some research datas are pointed out, and its generation is relevant with following risk factor: gene, environment and gene/environment common factor.Such as be not true to type that (dysplasia) nevus or melanoma family history, photoconduction cause Pigmented skin, are not easy tanning, red hair ethnic group, strong interruption Sunlight exposure, sunburn, multiple melanocytic naevi etc.Gene/environment many factors causes Melanoma Malignant to transform.The key cells path of vicious transformation: Rb path, p53 path, PI3K/AKT path, RAS/MAPK path (20 ~ 30%NRAS suddenlys change, and 55 ~ 60%BRAF suddenlys change).
The clinical symptoms of CMM, comprise hemorrhage, pruritus, tenderness, ulcer etc., in general, melanomatous symptom is relevant to age of onset, young patient generally shows as pruritus, the color of skin lesion changes and boundary expands, gerontal patient generally shows as skin lesion and occurs ulcer, usually points out prognosis mala.The skin lesion performance of CMM is relevant to the growth pattern of the region of anatomy and tumor, namely relevant to histological type, and histological type has very big-difference because of the difference of age, type, race again.Dissimilar melanoma has the different causes of disease and genetic background, and current melanomatous clinical tissue credit type adopts Clark typing, comprises four types: lentigo maligna melanoma (LMM); Superficial spreading melanoma; Acra freckle sample melanoma/mucosal melanoma; Nodular melanoma (NM).In the white people suffering from malignant melanoma, about 70% is SSM.But in the Aisan of all malignant melanomas, the ALM betiding less sun exposure position accounts for 72%.
Clinical is at present answer excision to the infringement do not shifted in early days for melanomatous Therapeutic Principle, the scope of excising skin lesion periphery normal skin should be determined according to the Breslow degree of depth, if refer to (toe) malignant melanoma, can adopt and cut finger (toe) art.Involved lymph nodes should be excised, but preventative lymph node resection is still disputable.Perfusion of limb anti-mitosis medicine treatment limbs melanoma has certain curative effect.Although biochemotherapy and molecular targeted therapy have very large prospect, combined chemotherapy and radiotherapy is adopted to be still topmost therapeutic modality for the melanoma patients that extensively transfer occurs.The present invention aims to provide a kind of determined curative effect and the low melanoma medicine of toxic and side effects.
In prior art, chemotherapy course is comparatively large to the side effect of melanoma patients, and can not be satisfactory for killing of melanoma cell.In order to overcome above-mentioned the deficiencies in the prior art, the object of this invention is to provide one and can treat melanomatous Chinese medicine composition, it significantly can kill melanoma cell, is applicable to being developed to melanoma medicine.
One treats melanomatous Chinese medicine composition, it is made up of the raw material of following weight: Herba Cistanches 8-20 part, Rhizoma Polygoni Cuspidati 5-15 part, Herba Andrographis 5-15 part, Fructus Corni 3-10 part, Semen Cuscutae 10-25 part, Radix Morindae Officinalis 5-15 part, Cortex Eucommiae 10-20 part, Fructus Trichosanthis leaf 3-10 part, Rhizoma Acori Graminei 10-20 part, Radix Et Rhizoma Rhei 8-20 part, Radix Morinae Bulleyanae 5-12 part, Radix Dipsaci 10-20 part, Concha Ostreae 3-10 part, Rhizoma Pinelliae 5-15 part, Fructus Crataegi 3-10 part, Herba Epimedii 3-10 part, Radix Rehmanniae Preparata 5-12 part, Rhizoma Sparganii 10-15 part, Fructus Ligustri Lucidi 10-20 part, Radix Cynanchi Paniculati 3-10 part, Ramulus Cinnamomi 5-15 part, Radix Bupleuri 5-15 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 5-25 part, Folium Isatidis 10-20 part,
The above-mentioned Chinese medicine of the present invention is clinical conventional Chinese medicine, and its medicinal part is well known to the skilled person, and described Chinese medicine composition significantly can alleviate the toxic and side effects in melanoma therapeutic process after reasonable compatibility, and heightens the effect of a treatment.Reinforced effects melanoma cell in melanoma medicine or radiation therapy process killed according to Chinese medicine composition and the difference alleviating effect for toxic and side effects in therapeutic process, inventor is preferably as follows on above-mentioned Chinese medicine composition basis:
(1) Herba Cistanches 15 parts, Rhizoma Polygoni Cuspidati 10 parts, Herba Andrographis 10 parts, Fructus Corni 7 parts, Semen Cuscutae 18 parts, Radix Morindae Officinalis 10 parts, the Cortex Eucommiae 15 parts, 7 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 15 parts, Radix Et Rhizoma Rhei 14 parts, Radix Morinae Bulleyanae 9 parts, Radix Dipsaci 15 parts, Concha Ostreae 7 parts, the Rhizoma Pinelliae 10 parts, Fructus Crataegi 7 parts, Herba Epimedii 6 parts, 8 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 13 parts, Fructus Ligustri Lucidi 15 parts, Radix Cynanchi Paniculati 7 parts, Ramulus Cinnamomi 10 parts, Radix Bupleuri 10 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 20 parts, Folium Isatidis 15 parts.
(2) Herba Cistanches 8 parts, Rhizoma Polygoni Cuspidati 5 parts, Herba Andrographis 5 parts, Fructus Corni 3 parts, Semen Cuscutae 10 parts, Radix Morindae Officinalis 5 parts, the Cortex Eucommiae 10 parts, 3 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 10 parts, Radix Et Rhizoma Rhei 8 parts, Radix Morinae Bulleyanae 5 parts, Radix Dipsaci 10 parts, Concha Ostreae 3 parts, the Rhizoma Pinelliae 5 parts, Fructus Crataegi 3 parts, Herba Epimedii 3 parts, 5 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 10 parts, Fructus Ligustri Lucidi 10 parts, Radix Cynanchi Paniculati 3 parts, Ramulus Cinnamomi 5 parts, Radix Bupleuri 5 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 5 parts, Folium Isatidis 10 parts.
(3) Herba Cistanches 20 parts, Rhizoma Polygoni Cuspidati 15 parts, Herba Andrographis 15 parts, Fructus Corni 10 parts, Semen Cuscutae 25 parts, Radix Morindae Officinalis 15 parts, the Cortex Eucommiae 20 parts, 10 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 20 parts, Radix Et Rhizoma Rhei 20 parts, Radix Morinae Bulleyanae 12 parts, Radix Dipsaci 20 parts, Concha Ostreae 10 parts, the Rhizoma Pinelliae 15 parts, Fructus Crataegi 10 parts, Herba Epimedii 10 parts, 12 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 15 parts, Fructus Ligustri Lucidi 20 parts, Radix Cynanchi Paniculati 10 parts, Ramulus Cinnamomi 15 parts, Radix Bupleuri 15 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 25 parts, Folium Isatidis 20 parts.
(4) Herba Cistanches 12 parts, Rhizoma Polygoni Cuspidati 12 parts, Herba Andrographis 10 parts, Fructus Corni 5 parts, Semen Cuscutae 16 parts, Radix Morindae Officinalis 18 parts, the Cortex Eucommiae 13 parts, 6 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 20 parts, Radix Et Rhizoma Rhei 10 parts, Radix Morinae Bulleyanae 8 parts, Radix Dipsaci 16 parts, Concha Ostreae 6 parts, the Rhizoma Pinelliae 10 parts, Fructus Crataegi 5 parts, Herba Epimedii 8 parts, 7 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 8 parts, Fructus Ligustri Lucidi 14 parts, Radix Cynanchi Paniculati 10 parts, Ramulus Cinnamomi 5 parts, Radix Bupleuri 15 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 parts, Folium Isatidis 17 parts.
Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, mixture, tablet or capsule.The present invention also provides a kind of preparation method of above-mentioned Chinese medicine composition, it comprises the steps: that getting recipe quantity Chinese crude drug is broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in the melanomatous medicine of preparation treatment.Chinese medicine composition of the present invention has the effect of remarkable check melanin tumor cell proliferation and cell death inducing, the embodiment of the present invention 7 shows, Chinese medicine composition of the present invention is external all shows stronger inhibitory action to three kinds of melanoma cell strain (B16, A375 and SK-MEL-2) cell proliferation, the most remarkable with 25-100mg/mL concentration.Adopt AnnexinV and PI two dye Flow cytometry to show, Chinese medicine composition of the present invention shows stronger cell death inducing effect to human melanoma cell strain A375, is suitable for being developed to melanoma medicine.
Chinese medicine composition of the present invention, in treatment melanoma, compared with prior art has following advantage:
1) compared with current black element tumor medicine, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, significantly improve the compliance of melanoma patients, and improve the quality of life of patient.
2) in Chinese medicine composition of the present invention containing multi-medicament component, action target spot is numerous, and pharmacological evaluation shows it and has the effect significantly reducing toxic and side effects in chemotherapy process, improves its melanoma inhibition to melanoma cell.
Summary of the invention
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
(1) example of formulations part
Embodiment 1 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Herba Cistanches 80g, Rhizoma Polygoni Cuspidati 50g, Herba Andrographis 50g, Fructus Corni 30g, Semen Cuscutae 100g, Radix Morindae Officinalis 50g, Cortex Eucommiae 100g, Fructus Trichosanthis leaf 30g, Rhizoma Acori Graminei 100g, Radix Et Rhizoma Rhei 80g, Radix Morinae Bulleyanae 50g, Radix Dipsaci 100g, Concha Ostreae 30g, Rhizoma Pinelliae 50g, Fructus Crataegi 30g, Herba Epimedii 30g, Radix Rehmanniae Preparata 50g, Rhizoma Sparganii 100g, Fructus Ligustri Lucidi 100g, Radix Cynanchi Paniculati 30g, Ramulus Cinnamomi 50g, Radix Bupleuri 50g, Pseudobulbus Bletillae (Rhizoma Bletillae) 50g, Folium Isatidis 100g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 4 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40%, reflux, extract, three times, return time is 5h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
Embodiment 2 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Herba Cistanches 200g, Rhizoma Polygoni Cuspidati 150g, Herba Andrographis 150g, Fructus Corni 100g, Semen Cuscutae 250g, Radix Morindae Officinalis 150g, Cortex Eucommiae 200g, Fructus Trichosanthis leaf 100g, Rhizoma Acori Graminei 200g, Radix Et Rhizoma Rhei 200g, Radix Morinae Bulleyanae 120g, Radix Dipsaci 200g, Concha Ostreae 100g, Rhizoma Pinelliae 150g, Fructus Crataegi 100g, Herba Epimedii 100g, Radix Rehmanniae Preparata 120g, Rhizoma Sparganii 150g, Fructus Ligustri Lucidi 200g, Radix Cynanchi Paniculati 100g, Ramulus Cinnamomi 150g, Radix Bupleuri 150g, Pseudobulbus Bletillae (Rhizoma Bletillae) 250g, Folium Isatidis 200g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 90%, reflux, extract, three times, return time is 3h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
Embodiment 3 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Herba Cistanches 150g, Rhizoma Polygoni Cuspidati 100g, Herba Andrographis 100g, Fructus Corni 70g, Semen Cuscutae 180g, Radix Morindae Officinalis 100g, Cortex Eucommiae 150g, Fructus Trichosanthis leaf 70g, Rhizoma Acori Graminei 150g, Radix Et Rhizoma Rhei 140g, Radix Morinae Bulleyanae 90g, Radix Dipsaci 150g, Concha Ostreae 70g, Rhizoma Pinelliae 100g, Fructus Crataegi 70g, Herba Epimedii 60g, Radix Rehmanniae Preparata 80g, Rhizoma Sparganii 130g, Fructus Ligustri Lucidi 150g, Radix Cynanchi Paniculati 70g, Ramulus Cinnamomi 100g, Radix Bupleuri 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 200g, Folium Isatidis 150g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 70%, reflux, extract, three times, return time is 4h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
Embodiment 4 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Herba Cistanches 80g, Rhizoma Polygoni Cuspidati 150g, Herba Andrographis 150g, Fructus Corni 30g, Semen Cuscutae 250g, Radix Morindae Officinalis 150g, Cortex Eucommiae 100g, Fructus Trichosanthis leaf 100g, Rhizoma Acori Graminei 100g, Radix Et Rhizoma Rhei 160g, Radix Morinae Bulleyanae 120g, Radix Dipsaci 100g, Concha Ostreae 30g, Rhizoma Pinelliae 50g, Fructus Crataegi 100g, Herba Epimedii 100g, Radix Rehmanniae Preparata 70g, Rhizoma Sparganii 100g, Fructus Ligustri Lucidi 150g, Radix Cynanchi Paniculati 30g, Ramulus Cinnamomi 100g, Radix Bupleuri 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Folium Isatidis 100g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 70%, reflux, extract, three times, return time is 4h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Adding ethanol to alcohol content is 75% (v/v), leaves standstill 24 hours, gets supernatant, and reclaim ethanol and concentrate, add water to 1000ml, stir evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
Embodiment 5 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Herba Cistanches 120g, Rhizoma Polygoni Cuspidati 120g, Herba Andrographis 100g, Fructus Corni 50g, Semen Cuscutae 160g, Radix Morindae Officinalis 180g, Cortex Eucommiae 130g, Fructus Trichosanthis leaf 60g, Rhizoma Acori Graminei 200g, Radix Et Rhizoma Rhei 100g, Radix Morinae Bulleyanae 80g, Radix Dipsaci 160g, Concha Ostreae 60g, Rhizoma Pinelliae 100g, Fructus Crataegi 50g, Herba Epimedii 80g, Radix Rehmanniae Preparata 70g, Rhizoma Sparganii 80g, Fructus Ligustri Lucidi 140g, Radix Cynanchi Paniculati 100g, Ramulus Cinnamomi 50g, Radix Bupleuri 150g, Pseudobulbus Bletillae (Rhizoma Bletillae) 150g, Folium Isatidis 170g;
Preparation method is with embodiment 4.
Embodiment 6 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Herba Cistanches 140g, Rhizoma Polygoni Cuspidati 100g, Herba Andrographis 130g, Fructus Corni 60g, Semen Cuscutae 200g, Radix Morindae Officinalis 150g, Cortex Eucommiae 200g, Fructus Trichosanthis leaf 30g, Rhizoma Acori Graminei 160g, Radix Et Rhizoma Rhei 110g, Radix Morinae Bulleyanae 70g, Radix Dipsaci 160g, Concha Ostreae 70g, Rhizoma Pinelliae 110g, Fructus Crataegi 50g, Herba Epimedii 100g, Radix Rehmanniae Preparata 120g, Rhizoma Sparganii 150g, Fructus Ligustri Lucidi 160g, Radix Cynanchi Paniculati 100g, Ramulus Cinnamomi 150g, Radix Bupleuri 120g, Pseudobulbus Bletillae (Rhizoma Bletillae) 180g, Folium Isatidis 170g;
Preparation technology is with embodiment 4.
(2) test examples part
Embodiment 7: Chinese medicine composition of the present invention is to the inhibitory action of melanoma cell strain
1, cell strain: mouse melanin tumor cell strain (B16), purchased from Chinese Academy of Sciences's Shanghai cell bank.Human melanoma cell strain (A375 and SK-MEL-2) is purchased from ATCC.Above-mentioned cell strain with the DMEM culture medium containing 10% hyclone 37 DEG C, volume fraction be 5%CO2, completely saturated humidity condition under cellar culture, 48h replaced medium, when Growth of Cells reaches full conjunction state, by 0.25% trypsin+0.02%EDTA had digestive transfer culture, 2 ~ 3d goes down to posterity 1 time, and exponential phase cell is selected in experiment.
2, the detection of cell proliferation:
Adjusting B16, A375 and SK-MEL-2 cell strain concentration of cell suspension is respectively 1 × 105/mL, adds in 96 well culture plates, every hole 100 μ L, puts 37 DEG C of 5%CO2 incubators and cultivates 24h.Absorb old culture medium, (drug level is 100mg/mL, 50mg/mL to the plasma-free DMEM medium adding containing Chinese medicine composition of the present invention respectively, 25mg/mL, 5mg/mL), and establish blank group and zeroing group, often organize and all establish 3 multiple holes, continue to cultivate 24h.Add 10 μ LWST-8 solution, cultivate 2h.The light absorption value in each hole is detected at 490nm place.Cell proliferation inhibition rate=(1-(dosing group OD meansigma methods-zeroing hole OD meansigma methods)/(blank group OD meansigma methods-zeroing hole OD meansigma methods)) × 100%.Experiment repetition more than 3 times.
3, apoptotic detection
Adjustment A375 concentration of cell suspension is 1 × 10
6/ mL, is inoculated in 6 orifice plates by cell, every hole 1ml.Reach after Fusion Strain until Growth of Cells, former culture medium is abandoned in suction, add containing Chinese medicine composition of the present invention that (drug level is 100mg/mL respectively, 50mg/mL, 25mg/mL, plasma-free DMEM medium 5mg/mL), blank group adds the culture medium containing 0.1%DMSO, after drug effect 24h, cell conditioned medium is drawn in centrifuge tube, cell is after trypsinization, move in the centrifuge tube identical with cell conditioned medium, 1000rpm4 DEG C of centrifugal 5min, abandon supernatant, 1 time is washed with PBS, abandon supernatant, 1 time is washed with Bindingbuffer, and it is resuspended with 195 μ LBindingbuffer, after 5 μ LAnnexinV-FITC mix, room temperature lucifuge hatches 10 minutes, 1 time is washed with Bindingbuffer, and it is resuspended with 190 μ LBindingbuffer, add 10 μ LPI and mix machine testing on rear flow cytometer.
4 experimental results
The testing result that 4.1 Chinese medicine compositions of the present invention affect three kinds of melanoma cell strain cell proliferation
The testing result that table 1 Chinese medicine composition of the present invention affects three kinds of melanoma cell strain cell proliferation
| Drug level | B16 cell inhibitory rate | A375 cell inhibitory rate | SK-MEL-2 cell inhibitory rate |
| 5mg/mL | 22.3％ | 17.2％ | 30.5％ |
| 25mg/mL | 58.6％ | 58.4％ | 44.9％ |
| 50mg/mL | 70.6％ | 75.9％ | 62.1％ |
| 100mg/mL | 81.2％ | 91.8％ | 86.4％ |
WST-8 is the method detecting cell proliferation and toxicity comparatively advanced person.This experimental result shows, and Chinese medicine composition of the present invention is external all shows stronger inhibitory action to three kinds of melanoma cell strain (B16, A375 and SK-MEL-2) cell proliferation, the most remarkable with 25-100mg/mL concentration.
4.2, Chinese medicine composition of the present invention is to the testing result of human melanoma cell strain A375 Apoptosis
AnnexinV and PI two dye Flow cytometry is adopted to show, Chinese medicine composition of the present invention shows stronger cell death inducing effect to human melanoma cell strain A375, be 100mg/mL at drug level, 50mg/mL, in the culture medium of 25mg/mL, 5mg/mL, the apoptosis rate of A375 cell strain is respectively 85%, 90%, 25% and 15% is the most remarkable with 50-100mg/mL concentration.
Claims (8)
1. the melanomatous Chinese medicine composition for the treatment of, it is characterized in that, described Chinese medicine composition obtains primarily of the raw material of following weight portion: Herba Cistanches 8-20 part, Rhizoma Polygoni Cuspidati 5-15 part, Herba Andrographis 5-15 part, Fructus Corni 3-10 part, Semen Cuscutae 10-25 part, Radix Morindae Officinalis 5-15 part, Cortex Eucommiae 10-20 part, Fructus Trichosanthis leaf 3-10 part, Rhizoma Acori Graminei 10-20 part, Radix Et Rhizoma Rhei 8-20 part, Radix Morinae Bulleyanae 5-12 part, Radix Dipsaci 10-20 part, Concha Ostreae 3-10 part, Rhizoma Pinelliae 5-15 part, Fructus Crataegi 3-10 part, Herba Epimedii 3-10 part, Radix Rehmanniae Preparata 5-12 part, Rhizoma Sparganii 10-15 part, Fructus Ligustri Lucidi 10-20 part, Radix Cynanchi Paniculati 3-10 part, Ramulus Cinnamomi 5-15 part, Radix Bupleuri 5-15 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 5-25 part, Folium Isatidis 10-20 part.
2. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition obtains primarily of the raw material of following weight portion: Herba Cistanches 15 parts, Rhizoma Polygoni Cuspidati 10 parts, Herba Andrographis 10 parts, Fructus Corni 7 parts, Semen Cuscutae 18 parts, Radix Morindae Officinalis 10 parts, the Cortex Eucommiae 15 parts, 7 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 15 parts, Radix Et Rhizoma Rhei 14 parts, Radix Morinae Bulleyanae 9 parts, Radix Dipsaci 15 parts, Concha Ostreae 7 parts, the Rhizoma Pinelliae 10 parts, Fructus Crataegi 7 parts, Herba Epimedii 6 parts, 8 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 13 parts, Fructus Ligustri Lucidi 15 parts, Radix Cynanchi Paniculati 7 parts, Ramulus Cinnamomi 10 parts, Radix Bupleuri 10 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 20 parts, Folium Isatidis 15 parts.
3. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition obtains primarily of the raw material of following weight portion: Herba Cistanches 8 parts, Rhizoma Polygoni Cuspidati 5 parts, Herba Andrographis 5 parts, Fructus Corni 3 parts, Semen Cuscutae 10 parts, Radix Morindae Officinalis 5 parts, the Cortex Eucommiae 10 parts, 3 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 10 parts, Radix Et Rhizoma Rhei 8 parts, Radix Morinae Bulleyanae 5 parts, Radix Dipsaci 10 parts, Concha Ostreae 3 parts, the Rhizoma Pinelliae 5 parts, Fructus Crataegi 3 parts, Herba Epimedii 3 parts, 5 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 10 parts, Fructus Ligustri Lucidi 10 parts, Radix Cynanchi Paniculati 3 parts, Ramulus Cinnamomi 5 parts, Radix Bupleuri 5 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 5 parts, Folium Isatidis 10 parts.
4. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition obtains primarily of the raw material of following weight portion: Herba Cistanches 20 parts, Rhizoma Polygoni Cuspidati 15 parts, Herba Andrographis 15 parts, Fructus Corni 10 parts, Semen Cuscutae 25 parts, Radix Morindae Officinalis 15 parts, the Cortex Eucommiae 20 parts, 10 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 20 parts, Radix Et Rhizoma Rhei 20 parts, Radix Morinae Bulleyanae 12 parts, Radix Dipsaci 20 parts, Concha Ostreae 10 parts, the Rhizoma Pinelliae 15 parts, Fructus Crataegi 10 parts, Herba Epimedii 10 parts, 12 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 15 parts, Fructus Ligustri Lucidi 20 parts, Radix Cynanchi Paniculati 10 parts, Ramulus Cinnamomi 15 parts, Radix Bupleuri 15 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 25 parts, Folium Isatidis 20 parts.
5. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition obtains primarily of the raw material of following weight portion: Herba Cistanches 12 parts, Rhizoma Polygoni Cuspidati 12 parts, Herba Andrographis 10 parts, Fructus Corni 5 parts, Semen Cuscutae 16 parts, Radix Morindae Officinalis 18 parts, the Cortex Eucommiae 13 parts, 6 parts, Fructus Trichosanthis leaf, Rhizoma Acori Graminei 20 parts, Radix Et Rhizoma Rhei 10 parts, Radix Morinae Bulleyanae 8 parts, Radix Dipsaci 16 parts, Concha Ostreae 6 parts, the Rhizoma Pinelliae 10 parts, Fructus Crataegi 5 parts, Herba Epimedii 8 parts, 7 parts, Radix Rehmanniae Preparata, Rhizoma Sparganii 8 parts, Fructus Ligustri Lucidi 14 parts, Radix Cynanchi Paniculati 10 parts, Ramulus Cinnamomi 5 parts, Radix Bupleuri 15 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 parts, Folium Isatidis 17 parts.
6. the Chinese medicine composition as described in as arbitrary in claim 1-5, it is characterized in that, described Chinese medicine composition is powder, mixture, tablet or capsule.
7. prepare the method for the arbitrary described Chinese medicine composition of claim 1-5 for one kind, it is characterized in that, described preparation method comprises the steps: that getting recipe quantity Chinese crude drug is broken into coarse powder, adds according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filter, filtrate reclaims ethanol, cold filtration after merging, wash with water, after drying, namely obtain Chinese medical concrete; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically in this preparation method.
8. the purposes of the arbitrary described Chinese medicine composition of claim 1-5 in the melanomatous medicine of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510561135.XA CN105169143B (en) | 2015-09-07 | 2015-09-07 | A kind of Chinese medicine composition treating melanoma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510561135.XA CN105169143B (en) | 2015-09-07 | 2015-09-07 | A kind of Chinese medicine composition treating melanoma and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105169143A true CN105169143A (en) | 2015-12-23 |
| CN105169143B CN105169143B (en) | 2016-07-20 |
Family
ID=54891891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510561135.XA Expired - Fee Related CN105169143B (en) | 2015-09-07 | 2015-09-07 | A kind of Chinese medicine composition treating melanoma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105169143B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497810A (en) * | 2016-01-20 | 2016-04-20 | 青岛云天生物技术有限公司 | Pharmaceutical composition for treating malignant melanoma and application thereof |
| CN116574144A (en) * | 2023-03-13 | 2023-08-11 | 河南中医药大学 | Method for preparing cornuside F from cornus officinalis leaves and application of cornuside F |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279090A (en) * | 1999-06-25 | 2001-01-10 | 刘永香 | Powdered medicine for conditioning viscera and whole body |
| CN102107009A (en) * | 2009-12-25 | 2011-06-29 | 奇复康药物研发(苏州)有限公司 | Mixed compound medicament of natural medicament components and nitric oxide donors and application thereof |
-
2015
- 2015-09-07 CN CN201510561135.XA patent/CN105169143B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279090A (en) * | 1999-06-25 | 2001-01-10 | 刘永香 | Powdered medicine for conditioning viscera and whole body |
| CN102107009A (en) * | 2009-12-25 | 2011-06-29 | 奇复康药物研发(苏州)有限公司 | Mixed compound medicament of natural medicament components and nitric oxide donors and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 段桂卿: "中医治疗恶性黑色素瘤三例", 《南京中医药大学学报(自然科学版)》 * |
| 阎晓天等: "中医治疗皮肤癌临床及实验研究概况", 《中国中医药科技》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497810A (en) * | 2016-01-20 | 2016-04-20 | 青岛云天生物技术有限公司 | Pharmaceutical composition for treating malignant melanoma and application thereof |
| CN116574144A (en) * | 2023-03-13 | 2023-08-11 | 河南中医药大学 | Method for preparing cornuside F from cornus officinalis leaves and application of cornuside F |
| CN116574144B (en) * | 2023-03-13 | 2024-02-20 | 河南中医药大学 | Method for preparing cornuside F from cornus officinalis leaves and application of cornuside F |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105169143B (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014139282A1 (en) | Pharmaceutical compositions for treating cancer of genital system and preparation method therefor | |
| CN104491766B (en) | One treats melanomatous Chinese medicine composition and preparation method thereof | |
| WO2012139314A1 (en) | Chinese herbal medicinal composition for treating cancer | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN105169143B (en) | A kind of Chinese medicine composition treating melanoma and preparation method thereof | |
| CN103157014B (en) | Miao medicine for treating tumors | |
| CN103830527A (en) | Preparation for treating prostatitis | |
| CN103877508A (en) | Traditional Chinese medicine composition for treating metrocarcinoma | |
| CN111481638A (en) | Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof | |
| CN102579999A (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN102805844A (en) | Medicine for treating liver cancer | |
| CN105213584A (en) | A kind of Chinese medicine composition for the treatment of eczema and preparation method thereof | |
| CN103536850A (en) | Traditional Chinese medicine for treating verruca plana from inside and outside | |
| CN113769003A (en) | Medicine for treating hyperplasia of mammary glands and breast tumor and preparation method thereof | |
| CN104888149A (en) | Drug for treating cervical cancer and preparation method for drug | |
| CN105012552A (en) | Traditional Chinese medicine for treating wind-prevailing migratory arthralgia type rheumatic arthritis and preparation method | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN104940617A (en) | Traditional Chinese medicine for treatment of qi-stagnation and blood stasis type chronic pyelonephritis and preparation method | |
| CN104042944A (en) | Medicinal preparation used for treating chloasma | |
| CN103055094B (en) | Traditional Chinese medicine for treating leukemia and preparation method thereof | |
| CN114869987B (en) | Traditional Chinese medicine composition for preventing liver cancer | |
| CN105497810A (en) | Pharmaceutical composition for treating malignant melanoma and application thereof | |
| CN106421074A (en) | Traditional Chinese medicine composition with anti-cancer and anti-tumor functions and preparation method thereof | |
| CN106620144B (en) | Traditional Chinese medicine preparation for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN105770515A (en) | Traditional Chinese medicinal composition for treating prostatitis and preparation method of traditional Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Jiang Zhikui Inventor after: Gong Liyan Inventor after: Mo Pengtao Inventor before: Zou Shidong |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160613 Address after: Qingdao City, Shandong province 266000 four Road No. 127 Applicant after: Zhongxin Hospital, Qingdao Address before: Qin village 277799 Shandong city of Linyi province Lanling County No. 149 Bian Zhen Applicant before: Zou Shidong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160720 Termination date: 20170907 |